RU2007121808A - Радиационная дозиметрия, блокирующие антитела: способы и применение в лечении рака - Google Patents
Радиационная дозиметрия, блокирующие антитела: способы и применение в лечении рака Download PDFInfo
- Publication number
- RU2007121808A RU2007121808A RU2007121808/14A RU2007121808A RU2007121808A RU 2007121808 A RU2007121808 A RU 2007121808A RU 2007121808/14 A RU2007121808/14 A RU 2007121808/14A RU 2007121808 A RU2007121808 A RU 2007121808A RU 2007121808 A RU2007121808 A RU 2007121808A
- Authority
- RU
- Russia
- Prior art keywords
- dose
- resection cavity
- hsrp
- interest
- surgically created
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 43
- 230000005855 radiation Effects 0.000 title claims abstract 20
- 230000000903 blocking effect Effects 0.000 title claims 9
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 201000011510 cancer Diseases 0.000 title 1
- 238000004980 dosimetry Methods 0.000 title 1
- 238000002271 resection Methods 0.000 claims abstract 25
- 230000014759 maintenance of location Effects 0.000 claims abstract 11
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims 16
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 3
- 102000007000 Tenascin Human genes 0.000 claims 3
- 108010008125 Tenascin Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- -1 cytosinomycininosine Chemical compound 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- 206010067484 Adverse reaction Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 230000006838 adverse reaction Effects 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 108010066676 Abrin Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000007547 Laminin Human genes 0.000 claims 1
- 108010085895 Laminin Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 229930191564 Monensin Natural products 0.000 claims 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims 1
- 102100037369 Nidogen-1 Human genes 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102000016611 Proteoglycans Human genes 0.000 claims 1
- 108010067787 Proteoglycans Proteins 0.000 claims 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- UDLWSISPUSEJTG-UHFFFAOYSA-N Verrucarin A Natural products CC1CCOC(=O)C=CCCC(=O)OC2CC3OC4C=C(C)CCC4(COC(=O)C1O)C2(C)C35CO5 UDLWSISPUSEJTG-UHFFFAOYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 229930188522 aclacinomycin Natural products 0.000 claims 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 1
- 229960004176 aclarubicin Drugs 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 229960005358 monensin Drugs 0.000 claims 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 108010008217 nidogen Proteins 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- 238000011363 radioimmunotherapy Methods 0.000 claims 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229930013292 trichothecene Natural products 0.000 claims 1
- 150000003327 trichothecene derivatives Chemical class 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- NLUGUZJQJYVUHS-IDXDZYHTSA-N verrucarin A Chemical compound C([C@@]12[C@@]3(C)[C@@]45CCC(C)=C[C@H]4O[C@@H]1C[C@H]3OC(=O)\C=C/C=C/C(=O)OCC[C@H]([C@@H](C(=O)OC5)O)C)O2 NLUGUZJQJYVUHS-IDXDZYHTSA-N 0.000 claims 1
- NLUGUZJQJYVUHS-UHFFFAOYSA-N verrucarina A Natural products C1OC(=O)C(O)C(C)CCOC(=O)C=CC=CC(=O)OC2CC3OC4C=C(C)CCC41C2(C)C31CO1 NLUGUZJQJYVUHS-UHFFFAOYSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1014—Intracavitary radiation therapy
- A61N5/1015—Treatment of resected cavities created by surgery, e.g. lumpectomy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62890204P | 2004-11-17 | 2004-11-17 | |
| US62874004P | 2004-11-17 | 2004-11-17 | |
| US60/628,740 | 2004-11-17 | ||
| US60/628,902 | 2004-11-17 | ||
| PCT/US2005/041884 WO2006073586A2 (en) | 2004-11-17 | 2005-11-17 | Radiation dosimetry and blocking antibodies and methods and uses threfor in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007121808A true RU2007121808A (ru) | 2008-12-27 |
Family
ID=36647943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007121808/14A RU2007121808A (ru) | 2004-11-17 | 2005-11-17 | Радиационная дозиметрия, блокирующие антитела: способы и применение в лечении рака |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060127311A1 (enExample) |
| EP (1) | EP1817062A4 (enExample) |
| JP (1) | JP2008520707A (enExample) |
| AU (1) | AU2005323377A1 (enExample) |
| CA (1) | CA2587172A1 (enExample) |
| RU (1) | RU2007121808A (enExample) |
| WO (1) | WO2006073586A2 (enExample) |
| ZA (1) | ZA200704642B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2681790A1 (en) * | 2007-03-30 | 2008-10-09 | F. Hoffmann-La Roche Ag | Composition of labeled and non-labeled monoclonal antibodies |
| CN114404429B (zh) * | 2021-11-30 | 2023-06-30 | 重庆医科大学附属第二医院 | 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用 |
| WO2024181576A1 (ja) * | 2023-03-02 | 2024-09-06 | 日本メジフィジックス株式会社 | 放射性金属標識抗体、放射性医薬、及び化合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| USRE38008E1 (en) * | 1986-10-09 | 2003-02-25 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US6787153B1 (en) * | 1991-06-28 | 2004-09-07 | Mitsubishi Chemical Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| AU6445894A (en) * | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| GB9314623D0 (en) * | 1993-07-14 | 1993-08-25 | Nordion Int Inc | Localization and therapy with agents directed against prostate specific antigen in breast cancer |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US6022521A (en) * | 1995-05-04 | 2000-02-08 | The Regents Of The University Of Michigan | Method of establishing the optimal radiation dose for radiopharmaceutical treatment of disease |
| WO1999036105A2 (en) * | 1998-01-16 | 1999-07-22 | Mca Development B.V. | USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE |
| ATE281184T1 (de) * | 1998-06-04 | 2004-11-15 | Coulter Pharm Inc | Patientenspezifische dosimetrie |
| ATE230614T1 (de) * | 1998-07-13 | 2003-01-15 | Univ Texas | Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten |
| US20020187100A1 (en) * | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
| US6455026B1 (en) * | 2001-03-23 | 2002-09-24 | Agy Therapeutics, Inc. | Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors |
| US7011814B2 (en) * | 2001-04-23 | 2006-03-14 | Sicel Technologies, Inc. | Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject |
-
2005
- 2005-11-16 US US11/282,115 patent/US20060127311A1/en not_active Abandoned
- 2005-11-17 RU RU2007121808/14A patent/RU2007121808A/ru not_active Application Discontinuation
- 2005-11-17 CA CA002587172A patent/CA2587172A1/en not_active Abandoned
- 2005-11-17 JP JP2007543288A patent/JP2008520707A/ja active Pending
- 2005-11-17 AU AU2005323377A patent/AU2005323377A1/en not_active Abandoned
- 2005-11-17 EP EP05856975A patent/EP1817062A4/en not_active Ceased
- 2005-11-17 WO PCT/US2005/041884 patent/WO2006073586A2/en not_active Ceased
-
2007
- 2007-06-13 ZA ZA200704642A patent/ZA200704642B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200704642B (en) | 2008-07-30 |
| EP1817062A2 (en) | 2007-08-15 |
| EP1817062A4 (en) | 2010-01-20 |
| WO2006073586A2 (en) | 2006-07-13 |
| WO2006073586A8 (en) | 2007-02-22 |
| US20060127311A1 (en) | 2006-06-15 |
| CA2587172A1 (en) | 2006-07-13 |
| AU2005323377A1 (en) | 2006-07-13 |
| JP2008520707A (ja) | 2008-06-19 |
| WO2006073586A3 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chua et al. | Emerging technologies for local cancer treatment | |
| Stewart et al. | Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. | |
| JP5889337B2 (ja) | Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法 | |
| Riva et al. | Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors | |
| Kobayashi et al. | Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation | |
| KR20100014809A (ko) | 열치료 서셉터 및 이를 사용하는 방법 | |
| Howell | Advancements in the use of Auger electrons in science and medicine during the period 2015–2019 | |
| US20060204443A1 (en) | Methods for tumor treatment using dendrimer conjugates | |
| EP0240990B1 (en) | Method and apparatus for selective irradiation of biological materials | |
| Wu et al. | Multimodal in vivo tracking of chimeric antigen receptor T cells in preclinical glioblastoma models | |
| AU2017283151A1 (en) | Modified dextran conjugates comprising a lysine-urea-glutamate pharmacophore | |
| JP6073508B2 (ja) | デンドリマー組成物、合成方法、及びそれらの使用 | |
| CN101321542A (zh) | 用于微动脉成像和放射治疗的微颗粒 | |
| Martínez‐Rovira et al. | Monte Carlo dose enhancement studies in microbeam radiation therapy | |
| RU2007121808A (ru) | Радиационная дозиметрия, блокирующие антитела: способы и применение в лечении рака | |
| JP7431940B2 (ja) | 腫瘍を治療するための方法 | |
| Klingebiel et al. | [131I]-Metaiodobenzylguanidine in the treatment of metastatic neuroblastoma: Clinical, pharmacological and dosimetric aspects | |
| US20070280418A1 (en) | Coupled Carriers for Enhancing Therapy | |
| Chen et al. | Imaging, biodistribution and efficacy evaluation of 188Re-human serum albumin microspheres via intraarterial route in an orthotopic hepatoma model | |
| Kim et al. | Direct and indirect chimeric antigen receptor T-Cell imaging with PET/MRI in a tumor xenograft model | |
| TWI833803B (zh) | 含有高ｚ元素之奈米顆粒在製備用於治療腫瘤之藥物之用途 | |
| WO2021230369A1 (ja) | 金ナノ粒子含有医薬 | |
| JP2008540429A (ja) | 癌の治療における併用療法 | |
| US8709380B1 (en) | Targeting agents for enhancing radiation therapy | |
| Vallera et al. | Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100115 |